

Lateral Flow Assays Market Projected to Reach \$14,128.7 million by 2030, at a CAGR of 5%, says Astute Analytica

CHICAGO, UNITED STATES, November 2, 2022 /EINPresswire.com/ -- The Global Lateral Flow Assay Market size was US\$ 9,165.7 million in 2021. The Global Lateral Flow Assay Market size is forecast to reach US\$ 14,128.7 million by 2030, growing at a CAGR of 5% during the forecast period from 2022 to 2030.

Request Sample Report at:

https://www.astuteanalytica.com/request-sample/lateral-flow-assays-market

The absence or presence of a target analyte, such as biomarkers or pathogens in animals or people, or contaminants in water supplies, foods, or animal feeds, can be determined using a diagnostic tool called a lateral



flow assay. The pregnancy test is the lateral flow quick test strip that is most well-known. However, in recent times, lateral flow tests have taken center stage for swiftly identifying COVID-19-causing SARS-CoV-2. Thus, the low-cost, straightforward, quick, and portable detection tools that are common in biomedicine, agriculture, food, and environmental sciences are made possible by lateral flow assays (LFAs).

Market Influencing Factors

Factors such as the need for quick diagnostic testing for COVID-19 and the increased majority of infectious diseases drive the global market expansion.

In order to stop the COVID-19 disease from spreading, the demand for rapid diagnostic testing had increased dramatically by the time it struck the world in 2020. Rapid test kits/rapid antigen testing are more frequently used to refer to COVID-19 lateral flow assays. Mucus collected with a nose or throat swab is typically used in rapid COVID-19 test kits. Because rapid antigen testing could identify the presence of COVID virus proteins even in the absence of symptoms, it was useful for halting the spread of the disease. It would be possible to detect asymptomatic people via rapid antigen testing (lateral flow) before they could spread the infection.

A lack of consistency in lateral flow assay results may slow the overall market growth.

Segmentation Overview

Indications, distribution channels, techniques, products & services, end-users, and regions are the segmentations evaluated for the Global Lateral Flow Assay Market analysis. On the basis of products & services, in 2021, the LFA kits maintain the highest market share of 71.9%. Based on indication, the infectious diseases segment acquired the highest share of 72.2% in the global market in 2021. Also, in terms of end-users, hospitals & clinics occupied the highest market share at 38.8% in 2021. On the basis of region, North America had the highest share of 34.9% of the market in 2021.

Regional Insights

In 2021, North America held the highest market share at 34.9%. Based on the country, the US acquired the highest shareholder in the region. The pressure of price and quality management is driving the demand for quick and decentralized testing, propelling the market growth in the region. In addition, on the basis of products and services, LFA kits segment accounted for the major share in the North America lateral flow assay market.

Europe accounted for the second-highest share of the market in 2021. On the basis of country, Western Europe has the highest market share; and Germany is likely to be the highest shareholder country, followed by the UK. Based on indication, the infectious diseases segment accounted for a major market share in 2021. Additionally, on the basis of infectious diseases, sexually transmitted diseases segment dominated the market share.

Asia Pacific is likely to exhibit the highest CAGR over the prediction period owing to the high prevalence of infectious and chronic disease cases in the world. In the region, China holds a dominant share, and India reports the highest annual growth rate over the prediction period owing to the rising population of these countries.

In the MEA market, South Africa held the highest share in 2021 and also reports the highest annual growth rate during the prediction period. Based on technique, the sandwich assays segment held the dominant place. In addition, on the basis of end-users, the hospitals and clinics accounted for the highest lateral flow assay market share of MEA.

In 2021, Brazil held the highest market share for lateral flow assays in South America, and it is likely to continue doing so over the next years. On the basis of distribution channels, the hospital pharmacies segment dominated the market share in 2021.

The major Companies in the Global Lateral Flow Assay Market are:

- Abbott Laboratories (Alere Inc) (United States)
- BioMérieux SA (France)
- PerkinElmer Incorporated (United States)
- Hologic Incorporated (United States)
- Other Prominent Players

Recent Developments by these Companies

Beckman Coulter, a diagnostic division of Danaher Corporation, declared in June 2021 that it has signed binding contracts with Quidel Corporation to acquire all rights pertaining to the production, marketing, and sale of a BNP assay for Beckman Coulter analyzers.

PerkinElmer introduced the highly sensitive point-of-care antigen test for mass screening in February 2021, which altered the COVID-19 quick testing environment. In asymptomatic or symptomatic patients, the lateral flow immunoassay test can help to screen for or help with the diagnosis of COVID-19.

Roche introduced the SARS-CoV-2 rapid antigen test in September 2020 in nations that recognize the CE mark, enabling quick triage choices at the point of treatment. The point-of-care SARS-CoV-2 fast antigen test can be used on both symptomatic and asymptomatic individuals.

The Siemens AG Clinitest quick COVID-19 antigen test, which can detect people infected with SARS-CoV-2 in 15 minutes, was introduced in Europe in October 2020.

Browse Detailed Summary of Research Report: https://www.astuteanalytica.com/industry-report/lateral-flow-assays-market

Segmentation Analysis

By Product & Services Segment Readers Bench-top Readers Hand-held Readers LFA Kits Test Strips Dipsticks

By Indications Segment Infectious Diseases

Cassettes Lancets

- o Mosquito-borne Diseases
- o Streptococcus Infections

- o Sexually Transmitted Diseases
- o Hepatitis
- o Tuberculosis
- o Asthma
- o Pneumonia
- o Sepsis
- o Gastrointestinal Infections
- o Others

Pregnancy Test

Drug Abuse Testing

By Technique Segment Sandwich Assays

Competitive Assays

Multiplex Detection Assays

By End User Segment

Hospitals & Clinics

Diagnostics Laboratories

Home Care Settings

Pharmaceuticals & Biotechnology Companies

Other

By Distribution Channel Segment

Hospital Pharmacies

Retail Pharmacies

Supermarkets/ Hypermarkets

e-Commerce

By Region Segment

North America

The U.S.

Canada

Mexico

Europe

Western Europe

The UK

Germany

France

Italy

Spain

Rest of Western Europe

Eastern Europe Poland Russia Rest of Eastern Europe

Asia Pacific China India Japan Australia & New Zealand ASEAN Rest of Asia Pacific

Middle East & Africa (MEA) UAE Saudi Arabia South Africa Rest of MEA

South America Brazil Argentina Rest of South America

Looking For Customization: https://www.astuteanalytica.com/ask-for-customization/lateral-flow-assays-market

About Astute Analytica

Astute Analytica is a global analytics and advisory company that has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in-depth, and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the Globe. They are able to make well-calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment-wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of best cost-effective, value-added package from us, should you decide to engage with us.

Aamir Beg
Astute Analytica
+1 888-429-6757
email us here
Visit us on social media:
Twitter
LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/599149641

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.